Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR142 | Q7Z601 | 6/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.41 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.41 |
| ▸ | PPID | Q08752 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.36 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2373607 | 0.85 | SIRT2 (0.44) | GPR142SIRT2HDAC1 | |
| SCHEMBL2374193 | 0.80 | PPID (0.42) | GPR142SIRT2PPIDHDAC1CLK1 | |
| SCHEMBL2376148 | 0.79 | PPID (0.41) | GPR142SIRT2PPIDHDAC1CLK1 | |
| SCHEMBL2374570 | 0.79 | PPID (0.48) | GPR142PPIDHDAC1CLK1MAPK8 | |
| SCHEMBL2374561 | 0.79 | PPID (0.48) | GPR142PPIDHDAC1CLK1MAPK8 | |
| SCHEMBL2374062 | 0.71 | PPID (0.44) | GPR142SIRT2PPIDHDAC1CLK1 | |
| SCHEMBL2374058 | 0.71 | PPID (0.44) | GPR142SIRT2PPIDHDAC1CLK1 | |
| SCHEMBL2374130 | 0.71 | PPID (0.47) | GPR142PPIDHDAC1CYP26A1ROCK2 | |
| SCHEMBL2373510 | 0.70 | PPID (0.50) | GPR142PPIDHDAC1CYP26A1ROCK2 | |
| SCHEMBL1124524 | 0.69 | ALDH1A1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224210-A1 | NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224210-A1 | NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS | CTSA, BECN1, HDAC6 | GPR142 3414/4885SIRT2 119/4885NOX1 2431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.